Please login to the form below

Not currently logged in

Saatchi & Saatchi create Spanish restless legs syndrome campaign

Online public awareness push is in collaboration with UCB


The Spanish arm of Saatchi & Saatchi Health has launched a new online campaign that aims to improve national public awareness of restless legs syndrome (RLS).

Uncovering Restless Legs Syndrome (Destapando el Síndrome de Piernas Inquietas) has been developed in partnership with Belgium-headquartered pharma company UCB and includes a website with associated blogs, forums and social networks.

The RLS microsite,, represent the central axis of the action and features information relating to the condition, its symptoms, treatment options, as well as testimonials from people living with RLS. The site also allows users to create their own infographics, with the added option of sharing these and personal comments via the site's Facebook page and Twitter feed.

Together with Saatchi & Saatchi Health and UCB, the project has been supported by a number of institutions, including the Spanish Society of Neurology, the Foundation of the Brain, the Spanish Society of Restless Legs Syndrome, the Research Institute of Sleep, and Centro Comercial Príncipe Pío.

RLS is characterised by unpleasant sensations in the legs, resulting in an uncontrollable urge to move to gain relief. The condition affects about 10 per cent of the population in Spain, many of whom have difficulty falling and staying asleep. While the underlying pathophysiology of RLS is not fully understood, it is thought to involve the central dopamine system.

Last year UCB's Parkinson's disease treatment, Neupro (rotigotine transdermal system), was approved in the US for use in the treatment for moderate-to-severe RLS. And in May this year, new data was published showing Neupro reduced total nocturnal systolic blood pressure (NSBP) elevations in people with RLS.

"RLS can be a serious condition with symptoms that can affect patients at any point in the day or night; and Parkinson's disease symptoms can have a broad impact on patients," said Dr William Ondo professor of the department of neurology at the University of Texas' Houston Medical School.

"Neupro provides a novel way of treating RLS and PD through continuous transdermal dopaminergic delivery. It can help patients manage the unpredictable nature of these chronic conditions." 

3rd July 2013

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...